Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis in Adults

 Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis in Adults

Janssens Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis

Shots:

  • The P-III OPTIMUM study results involve assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide, 14mg) in 1,133 patients with relapsing MS for 108wks. at 162 sites across the globe
  • The P-III OPTIMUM study results: 30.5% reduction in ARR (0.202 vs 0.290); 56% reduction in the number of CUALs; @12wks. CDA (10.1% vs 12.4%); safety profile is consistent with the previous studies
  • Ponesimod is an investigational S1P1 modulator, act by inhibiting S1P activity leading to a reduction in the number of circulating lymphocytes with its expected regulatory submission to the US FDA and EMA as a treatment for RMS based on the OPTIMUM study results

Click here to­ read full press release/ article | Ref: Johnson & Johnson | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post